Adam J. Gadzinksi, MD, MS, on the Impact of Telemedicine on Patient-Reported Outcomes

Video

The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.

Findings from a study presented at the Society of Urologic Oncology 21st Annual Meeting revealed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

The investigators ultimately discovered that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the implications of these study results.

Transcription:

I think for us, what we really took out of this was that patients were spending a lot just to come and see us in clinic. And that telemedicine, in terms of at least the outcomes of patient satisfaction, really was equivalent to in person visits. We had very complex discussions about very challenging cancer issues and decisions that patients had to make. And I think we found that having those discussions over telemedicine was pretty darn similar to in person visits.

And for certain parts of urologic cancer care, physical exam is not always the kind of hinge point of a decision and so you don't have to examine someone when you have their CT scan that you can review with them. You know, maybe they don't need to drive from eastern Washington 5 hours for you to, to you know, lay your hands on their abdomen and then look at the CT scan with them and make all of your cancer treatment decisions based on the CT scan.

There are some patients you do have to kind of see them in person and examine them in person before you decide on treatment decisions. And sometimes what we found is the telemedicine really streamlined their in person visit when they did come, so then when they come they're also getting, you know, a repeat CT scan, they’re getting labs, and so their trip to Washington, to Seattle, was more of a implementing a plan and less kind of discovering what that plan might be.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content